Search results
Aldeyra's ADX-2191 Aces Late-Stage Study In Rare Vision Disorder
Benzinga via Yahoo Finance· 2 years agoAldeyra Therapeutics Inc (NASDAQ: ALDX) achieved the primary endpoint in Part 1 of the Phase 3 GUARD...
Aldeyra Therapeutics Inc (NASDAQ: ALDX) achieved the primary endpoint in Part 1 of the Phase 3 GUARD...